Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...

In a perspective article published in Science, Professor Jonathan Rivnay explores next-generation bioelectronic medication.

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Key developments in the health sector include Abbott's profit boost from medical sales, the UK's assisted dying law debate, Donald Trump's reproductive remarks, BAT's synthetic nicotine launch, ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...

Robert Ford’s comments come as new CGMs and insulin pumps continue to roll out in the diabetes tech space, including over-the-counter glucose sensors.

Normoglycemic individuals spent 87% of their daily time in in the “tight range” of glucose levels (70-140 mg/dL) and the remainder above 140 mg/dL.

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

Even the most savvy patients with diabetes can err in adjusting insulin pumps for US seasonal time shifts, adding to the ...

Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...

STEVENS COUNTY, Wash. — Keith Johnson is recovering at Providence Saint Joseph's Medical Center thanks to his 13-year-old dog, Gita, who went to go get help for him after he fell and broke his hip.

Not everyone in the health field is so bullish on the prospects of CGMs for everyone, and question whether digging in too ...